Mechelen, Belgium; 19 September 2023, 22:01 CET; Galapagos NV (Euronext &
NASDAQ: GLPG) today announced that during its meeting of 19 September 2023, the
Board of Directors appointed Mr. Simon Sturge as Non-Executive Independent
Director by way of cooptation. Mr. Sturge replaces Dr. Mary Kerr who stepped
down on 18 September 2023.
Mr. Sturge brings over 40 years of international biotech and pharma experience
with leadership positions at Merck KGaA and Boehringer Ingelheim. He held CEO
roles at several biotech companies, including Kymab (now Sanofi) and Celltech
Biologics (now Lonza), and founded Ribotargets (now Vernalis). Mr. Sturge is
currently Chairman of the Board of Directors of MoonLake Immunotherapeutics,
Precerix and Mediar Therapeutics. He is also a member of the Board of Trustees
of Weizmann UK, part of Weizmann Institute, a renowned multidisciplinary
scientific research institute, and Our Future Health, a UK-based charity
organization. He previously was a member of the Boards of Nemesis BioScience,
Feedback plc, Silence Therapeutics, and Cristal Therapeutics.
"On behalf of Galapagos' Board of Directors, I am very pleased to welcome Simon
to our Board," said Dr. Paul Stoffels(1), CEO and Chairman of Galapagos. "Simon
is an accomplished life sciences leader and is well versed with global
experience in M&A, business transformations and commercial operations. His
extensive expertise in biologics manufacturing from decades of leadership roles
at Celltech Biologics, Merck KGaA and Boehringer Ingelheim, brings complementary
strategic insights to our Board and will be invaluable as we position our
company for long-term value creation."
"I am very honored to join the Board of Directors of Galapagos and I am excited
to work with this talented team that is dedicated to making a transformational
impact on the lives of patients worldwide," commented Mr. Sturge. "I look
forward to contributing to the company's ambition to accelerate science and
innovation in its strategic areas of immunology and oncology."
"The Board and I also want to sincerely thank Dr. Kerr for her important
contributions and commitment since she joined the Board in 2016. She has been
instrumental in guiding our company through many stages of development. It has
been a real pleasure working with her and I wish her all the best, both
personally and professionally. With the recent addition of Dr. Schaffert and the
appointment of Mr. Sturge to the Board, we are well positioned to maintain our
commitment to an experienced Board with diverse and complementary expertise,"
concluded Dr. Stoffels.
About Galapagos
Galapagos is a fully integrated biotechnology company united around a single
purpose: to transform patient outcomes through life-changing science
and innovation for more years of life and quality of life. We focus on the key
therapeutic areas of immunology and oncology, where we have developed deep
scientific expertise in multiple drug modalities, including small molecules and
cell therapies. Our portfolio comprises discovery through to commercialized
programs and our first medicine for rheumatoid arthritis and ulcerative colitis
is available in Europe and Japan. For additional information, please
visit www.glpg.com (http://www.glpg.com/) or follow us on LinkedIn
(https://www.globenewswire.com/Tracker?data=ezxJkwSFR72hjpmLV87_rCWHmXiEkJdYmJZA
mM2ogtGbwOFtqfgHUBEEFGXHaFo83cvmiDFpg4AEmLKK78dHsjgGmCaeMvJ36E2Ayj-
ezOHnYHIaUIAZlc1A0XmbkMKzClCPc7hEiPOvByRSfbsFQunjB9Mw2v2EXH653ri5widmmTRkrkre_FA
Y2bZEDq-VJC9NEfuFyUPT0A29gI-
p13O_hFuDoS9sZUqcxgX6JcnrwMRT63EZMXbky2R5cA0wPn3z0x5aqDb4BY1NBSLYewJzDF3OBhrblWA
hgWvClWvZVrI_FoJWrVp-KlQ91FztQeQrUb9bss1A59BpNVDQLuE5mW2kAbA-
lwKqe56rVnXPtYPdq2b7-
8gnY3_3Im5KOPoLjl9xR5WeSc7rBZ76O5rrd1J3p2c292_9pUauVIxKkxhwE-
JQpKN6DSA1L4EqK7XtUTAcJQw4l_jzaSKIBTNyxJDd3e4eo2KiYIn-zFqPBOqvSMIdJFYNDxr-
H4U5IzD_KAqNRLjM6QQ9ixbssNjrCtLrmd4DpeQX9EbGdypFqCboHKE2YNXgRYNzIppmf8br_LKU1eD5
fxZVMpzuFeeSpopW66cNapQM_k8YfhKBPvgRnuj06a3LGeWH2OzNwLZ4junayWghclaIgY6KtVwEXh_l
5jYtP8eUoBnsqgr5UVGRGLFPa8ZKbe20xzl_jPWftZaxCkIq8_iH2cs-oQ==) or Twitter
(https://www.globenewswire.com/Tracker?data=R498b57aPdjPPnpO80BvL5Dj20Y9F_la0Ss0
CxwYvDH8H56pXknrj_Md3DIU2_LoG9WbkunFYQ_mBbwylanRgyQA1xrVx2NE6O1MbiqeORMvKGc2yYso
qKnVQr8_LQyhOSXFgM01nLkEXHAmRH8ve5jiRThZeVD-
P95cNmE1Z6RNkXNiUEGyY89pziVjbXAGgpU0tDva-Dv9o0z80p58C-
J8fDfOMQFBY6HcSmpNclzdUyWHgdjP2ENXamg-LwvJSqCeZ1Xy4ZJA_krwQER-
lsJpuwUsO1wkBzcN7E_cPQVOvlNQ8OxyKaGqRpkxyEO8gLj9jBKPFlQ4LE1nQ2vhyjmst-
aJv2XFFvFrqvaXR5dW_4_IwYUu8MWzJa9m23v2w_zWgLD9PI30j_xCxTrugA7sOiEvHw9ALHiEjgu61T
Le-oLdpFcjekviEdsXkG-
leAzl17cVoc9YQo_yTB9FT_35A0hEm8QyAbcp5OtmFMnfLPQIRlCY5BcjeR8-
GeV13IvKT7yE8JHas4wlj4SSnE3pckT1EXou1yle_rmshbKTuIWS8VLedeuzxQT_TxgUMl5CbUmYtCRf
yXpUoqzPtfXywFbemSlAQt_7oPCcbm082dOus_7a-
0GpaCdE2tatiaUScKEYInlUFYco8vSRm1VUREUk3b9UhM9edL9C3BN0PU2f9-0n1GToRrvrW1htdBJg3
Eafs7tjYALDBZp9sQ==).
Contact
Media inquiries Investor inquiries
Marieke Vermeersch Sofie Van Gijsel
+32 479 490 603 +1 781 296 1143
media@glpg.com (mailto:media@glpg.com) ir@glpg.com (mailto:ir@glpg.com)
Sandra Cauwenberghs
ir@glpg.com (mailto:ir@glpg.com)
Forward-looking statements
This press release may include forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but not always,
made through the use of words or phrases such as "will," "long-term," and
"forward," and any similar expressions. These statements include, but are not
limited to, statements regarding the appointment of a new director. Any forward-
looking statements in this press release are based on our management's current
expectations and beliefs, and are not guarantees of future performance. Forward-
looking statements may involve unknown and known risks, uncertainties and other
factors which might cause our actual results, performance, or achievements to be
materially different from any historic or future results, performance, or
achievements expressed or implied by such statements. These risks, uncertainties
and other factors include, without limitation, the risk that we may not be able
to realize the expected benefits from the appointment of the new director. A
further list and description of these risks, uncertainties and other factors can
be found in our filings and reports with the Securities and Exchange Commission
(SEC), including in our most recent annual report on Form 20-F filed with the
SEC, as supplemented and/or modified by any other filings and reports that we
have made or will make with the SEC in the future. Given these risks and
uncertainties, the reader is advised not to place any undue reliance on such
forward-looking statements. In addition, even if our results, performance, or
achievements are consistent with such forward-looking statements, they may not
be predictive of results, performance, or achievements in future periods. These
forward-looking statements speak only as of the date of publication of this
press release. We expressly disclaim any obligation to update any forward-
looking statements in this press release, unless required by law or regulation.
--------------------------------------------------------------------------------
(1) Throughout this press release, 'Dr. Paul Stoffels' should be read as 'Dr.
Paul Stoffels, acting via Stoffels IMC BV'
Â